Pulmatrix doses first patient in Phase 2b trial of PUR1900 for ABPA with asthma

Pulmatrix, Inc.

First patient dosed in randomized, double-blind, placebo-controlled Phase 2b study of inhaled itraconazole (PUR1900) for ABPA in asthma.
Study targets 30 subjects across US, UK, Australia, France; 3 arms: placebo, 20 mg, 40 mg daily for 16 weeks plus 8-week follow-up.
Partnership with Cipla; proof-of-concept data expected by mid-2024.
PUR1900 aims to be first approved ABPA treatment, reducing systemic side effects of oral antifungals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.